• metastatic, hormone-sensitive prostate cancer 11
• renal cell cancer (RCC)

 

• immune chekpoint inhibitors
• anti-PD-(L)1
• atezolizumab based treatment
• atezolizumab alone
• atezolizumab plus bevacizumab
• avelumab based treatment
• avelumab plus axitinib
• nivolumab based treatment
• nivolumab alone
• nivolumab plus cabozantinib
• pembrolizumab based treatment
• pembrolizumab alone
• pembrolizumab plus axitinib
• pembrolizumab plus lenvatinib
• Immune checkpoint association
• nivolumab plus ipilimumab
• mTOR inhibitors
• everolimus
• lenvatinib plus everolimus
• VEGF(R) inhibitor
• lenvatinib
• lenvatinib in association

• versus all
• vs immune chekpoint inhibitors
• vs anti-PD-(L)1
• vs nivolumab based treatment
• vs nivolumab alone
• vs Immune checkpoint association
• vs nivolumab plus ipilimumab
• vs mTOR inhibitors
• vs everolimus
• vs non active control
• vs no additional treatment
• vs placebo
• vs VEGF(R) inhibitor
• vs pazopanib
• vs sunitinib

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)

Pathology:  metastatic/advanced RCC (mRCC) - 1st line (L1);